Literature DB >> 11141342

Clinical implications of disturbances of uterine vascular morphology and function.

M Hickey1, I S Fraser.   

Abstract

Menstrual disturbances are one of the most common problems presenting to the gynaecologist. In order for the endometrium to bleed, vessels must break down. Disruption in the regulation of endometrial vascular growth and function has been found in association with spontaneous and sex steroid-induced disturbances of menstrual bleeding. Although circulating oestrogens and progestogens influence the endometrial vessels, this effect appears to be indirect, and regulation is primarily via local factors. Deficient vasoconstriction and haemostasis with excessive fibrinolysis is seen in menorrhagia. Breakthrough bleeding in users of progestogen-only contraceptives is associated with increased superficial vascular fragility and disruptions in the supporting basement membrane. Blood vessels in uterine fibroids are abnormal in distribution and appearance. Adenomyosis is also commonly associated with menstrual disturbance, and alterations in vascular distribution suggest altered angiogenesis. Successful human embryo implantation requires endometrial vascular breakdown. Excessive thrombosis associated with the antiphospholipid syndrome may interfere with this re-modelling and compromise implantation. Arteriovenous malformations are a rare but important cause of excessive or irregular vaginal bleeding. Abundant vessels with abnormal morphology, associated with aberrant angiogenesis can be seen, and embolization of these vessels may be an effective conservative treatment. Improved understanding of the regulation of the uterine vasculature is likely to lead to targeted therapies to prevent unscheduled vascular breakdown and to control menstrual disturbance at an endometrial level.

Entities:  

Mesh:

Year:  2000        PMID: 11141342     DOI: 10.1053/beog.2000.0136

Source DB:  PubMed          Journal:  Baillieres Best Pract Res Clin Obstet Gynaecol


  9 in total

1.  Failed angiographic embolization in uterine arteriovenous malformation: a case report and review of the literature.

Authors:  Rashmi Bagga; Preeti Verma; Neelam Aggarwal; Vanita Suri; J R Bapuraj; Naveen Kalra
Journal:  Medscape J Med       Date:  2008-01-16

2.  Uterine arteriovenous malformation.

Authors:  Hilwati Hashim; Ouzreiah Nawawi
Journal:  Malays J Med Sci       Date:  2013-03

3.  Down-regulation of angiopoietin-1 expression in menorrhagia.

Authors:  Peter Hewett; Sarbjit Nijjar; Munjiba Shams; Susan Morgan; Janesh Gupta; Asif Ahmed
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

4.  Acquired uterine arteriovenous malformation following dilation and curettage: a case report.

Authors:  Andela Manisha; Amardeep Tembhare
Journal:  Pan Afr Med J       Date:  2022-05-26

5.  Possible Loss of GABAergic Inhibition in Mice With Induced Adenomyosis and Treatment With Epigallocatechin-3-Gallate Attenuates the Loss With Improved Hyperalgesia.

Authors:  Yumei Chen; Bo Zhu; Hongping Zhang; Ding Ding; Xishi Liu; Sun-Wei Guo
Journal:  Reprod Sci       Date:  2014-02-03       Impact factor: 3.060

6.  Should helical tomotherapy replace brachytherapy for cervical cancer? Case report.

Authors:  Chen-Hsi Hsieh; Ming-Chow Wei; Yao-Peng Hsu; Ngot-Swan Chong; Yu-Jen Chen; Sheng-Mou Hsiao; Yen-Ping Hsieh; Li-Ying Wang; Pei-Wei Shueng
Journal:  BMC Cancer       Date:  2010-11-23       Impact factor: 4.430

7.  A case of congenital uterine arterio-venous malformation managed by hysterectomy.

Authors:  Rohit Bhoil; Vandana Raghuvanshi; Suhas Basavaiah
Journal:  Pol J Radiol       Date:  2015-04-19

8.  Congenital Uterine Arteriovenous Malformation Presenting as Postcoital bleeding: A Rare Presentation of a Rare Clinical Condition.

Authors:  Neha Agarwal; Seema Chopra; Neelam Aggarwal; Ujjwal Gorsi
Journal:  J Clin Imaging Sci       Date:  2017-02-27

9.  Uterine arteriovenous malformation with sudden heavy vaginal hemmorhage.

Authors:  Sarah T Selby; Marianne Haughey
Journal:  West J Emerg Med       Date:  2013-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.